Science & academia

This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.

A neuroscientist reviewing brain activity data on a monitor for an article about epilepsy drug RAP-219

New epilepsy drug cuts seizures by nearly 80% in mid-stage trial

By / / Good News For Humankind

Epilepsy drug RAP-219 has shown striking results in a mid-stage clinical trial, reducing seizures by a median of 77.8% in adults whose epilepsy had not responded to existing medications. Developed by Rapport Therapeutics, the drug works by precisely targeting overactive brain regions rather than broadly suppressing electrical activity across the whole brain. Nearly one in four participants became completely seizure-free during the eight-week study. The trial’s use of implanted neurostimulation devices provided objective, real-time brain data that strengthens confidence in the findings. Phase 3 trials are expected to begin in 2026.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention, for article on annual HIV injection

FDA approves twice-yearly lenacapavir HIV prevention shot with 99.9% effectiveness

By / / Good News For Humankind

Lenacapavir HIV prevention has reached a landmark moment: the FDA has approved the twice-yearly injectable drug — brand name Yeztugo — as the first long-acting PrEP option in history. Clinical trials showed it stopped transmission in more than 99.9% of participants, outperforming daily oral PrEP across tens of thousands of people. The breakthrough matters because adherence to daily medication has always been the weak point in HIV prevention, particularly in high-burden communities facing stigma and limited clinic access. Gilead has also signed royalty-free licensing agreements to supply affordable versions to 120 countries, prioritizing sub-Saharan Africa, Southeast Asia, and the Caribbean.

A researcher examining a vial in a cancer immunotherapy laboratory for an article about personalized mRNA cancer vaccine

Personalized mRNA vaccine keeps pancreatic cancer at bay six years after treatment

By / / Good news links

Personalized mRNA cancer vaccine shows remarkable results in a small but significant trial for pancreatic cancer, one of medicine’s most stubborn killers. Six years after treatment, seven of eight patients who mounted an immune response remain alive — extraordinary for a disease with a five-year survival rate below 13%. The custom-built vaccine targets genetic mutations unique to each patient’s tumor, training the immune system to eliminate remaining cancer cells after surgery. New findings suggest the immune response may be self-sustaining, with helper T cells replenishing the killer T cells that attack cancer. A larger Phase 2 trial is now underway.

A researcher examines lab samples under blue light for an article about HIV cure research — 12 words

Australian gene-editing researchers report early HIV cure breakthrough

By / / Good News For Humankind

HIV cure research has reached a rare milestone, with Australian scientists reporting early gene-editing results that exceeded their own expectations. The experimental approach targets the latent viral reservoir hidden inside immune cells — the biological obstacle that has defeated every previous cure attempt. Unlike antiretroviral therapy, which suppresses HIV indefinitely but cannot eliminate it, gene editing aims to permanently delete the virus’s genetic code. For the 39 million people living with HIV worldwide, a functional remission without daily medication would be genuinely transformative. Researchers urge caution, but describe themselves as overwhelmed by the results — a word scientists rarely use.

A surgical team performing a complex organ procedure for an article about bladder transplant surgery, for article on bladder transplant

California surgeons perform the world’s first successful bladder transplant

By / / Good News For Humankind

Bladder transplant surgery has been successfully performed on a human patient for the first time in medical history. Oscar Larrainzar, a 41-year-old California father of four, received a donor bladder and kidney simultaneously in early May 2025, after cancer treatment left him without either organ. He has since been taken off dialysis entirely. The procedure was developed over four years by surgeons at USC and UCLA, who now plan a formal clinical trial to refine the technique. For patients who have lost bladder function, transplantation is no longer theoretical.

A surgeon performing minimally invasive robotic surgery for an article about NeuroSafe prostate surgery, for article on NeuroSafe prostate cancer surgery

NeuroSafe prostate surgery nearly doubles odds of keeping erectile function after cancer treatment

By / / Good News For Humankind

NeuroSafe prostate surgery nearly doubles the chances of men retaining erectile function after prostate cancer treatment, according to the first large-scale clinical trial of the technique. Published in Lancet Oncology and presented at the 2025 European Association of Urology congress, the trial found 39% of NeuroSafe patients reported no or mild erectile dysfunction one year after surgery, compared to just 23% receiving standard care. The procedure works by freezing and examining prostate tissue mid-operation, letting surgeons spare surrounding nerves when it is safe to do so. For the 50,000 men diagnosed with prostate cancer in England each year, this advance offers a meaningful path forward without forcing a choice between cure and quality of life.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention, for article on annual HIV injection

Annual jab for HIV protection passes trial hurdle

By / / Good News For Humankind

A once-yearly HIV prevention shot has just cleared its first safety trial, with the drug lenacapavir still detectable in participants’ bodies a full 56 weeks after a single injection. That’s a hopeful sign for people who find daily prevention pills hard to maintain — whether because of stigma, unstable housing, or simply the grind of remembering. Earlier trials of twice-yearly lenacapavir already showed striking results, and researchers are now testing whether one shot a year could work just as well. With nearly 40 million people living with HIV globally, a prevention tool this simple could reshape what protection looks like — especially for communities where daily medication has never been realistic.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record, for article on nuclear fusion ignition

France runs fusion reactor for record 22 minutes

By / / Good News For Humankind

A fusion reactor in southern France has kept a hydrogen plasma stable for 1,337 seconds — more than 22 minutes — beating the previous record by roughly 25%. The WEST Tokamak pulled this off using just 2 megawatts of heating power, and crucially, without damaging the reactor’s interior, which is the part that has tripped up so many earlier attempts. The data feeds directly into ITER, the much larger international fusion project being built nearby. Net energy gain — the real threshold for practical fusion — still hasn’t been reliably crossed, and this milestone doesn’t change that. But each stable second brings the dream of clean, limitless energy closer to something the world can actually build.

Two people holding hands, for article on Parkinson's infusion device, for article on Onapgo approval

U.S. approves “milestone” Parkinson’s treatment for 2025 release

By / / Good News For Humankind

Onapgo, a new wearable approved by the FDA, will give Americans with Parkinson’s a continuous, non-surgical way to manage their symptoms when it launches in late 2025. The small device delivers a steady infusion of apomorphine under the skin, bypassing the digestive system entirely — a real advantage for a disease that often slows digestion and makes pills unpredictable. In trials, patients cut their daily “off” episodes — those rough stretches when medication wears off and tremors return — by nearly two and a half hours on average. The therapy has quietly helped European patients for about three decades, and its U.S. arrival opens a gentler path for the roughly one million Americans living with Parkinson’s, part of a growing global push toward more humane, individualized care.

A doctor reviewing a prescription pad in a clinical setting for an article about non-opioid pain drug approval

FDA approves first non-opioid pain drug in more than 20 years

By / / Good News For Humankind

The FDA’s approval of Journavx (suzetrigine), a first-in-class non-opioid pain drug, marks the most significant shift in acute pain treatment in over two decades. Developed by Vertex Pharmaceuticals, the drug blocks a specific sodium channel in the peripheral nervous system, stopping pain signals before they reach the brain without engaging the opioid pathways linked to addiction and overdose. Two rigorous clinical trials confirmed its effectiveness for moderate to severe acute pain. With more than 500,000 opioid overdose deaths in the U.S. since 1999, this approval offers patients and doctors a genuinely new choice — one that treats real pain without the shadow of dependence.